PEPT
REX Peptide ETF
REX Peptide ETF seeks to provide investors with exposure to companies involved in the development and commercialization of peptide-based therapeutics and related technologies.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 3.3 M
ASSETS UNDER MGMT
65 bp
EXPENSES
Fund Basics
| Inception date | Oct 13, 2026 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 13.4 % |
| ASCENDIS PHARMA A/S | 10.7 % |
| NOVO-NORDISK A/S-SPONS ADR | 10.1 % |
| INSULET CORP | 7.9 % |
| PROTAGONIST THERAPEUTICS, INC. | 6.4 % |
| SANOFI-AVENTIS | 6.0 % |
| RHYTHM PHARMACEUTICALS, INC. | 5.8 % |
| VIKING THERAPEUTICS, INC. | 3.9 % |
| DARLING INTERNATIONAL INC | 3.9 % |
| BACHEM HOLDING AG | 3.7 % |
Constituent Breakdown
| Number of holdings | 28 |
| Herfindahl-Hirschman Index | 665 |
| Wgt avg mkt cap (mns) | $194,466 |
| Large cap (>$10bn) | 51.2% |
| Mid cap ($2-10bn) | 33.5% |
| Small cap (<$2bn) | 8.6% |
| Developed mkts. | 96.4% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
| UNITED STATES | 54.7 % | |
| DENMARK | 23.5 % | |
| FRANCE | 9.1 % | |
| SWITZERLAND | 4.3 % | |
| CANADA | 2.3 % | |
| SWEDEN | 1.4 % | |
| JAPAN | 1.0 % |
Historical Performance
Standardized Performance (as of 10/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -- | -- | -- | -- | -- | -- | -- | -- |
| Dividend Yield | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Returns | -- | -- | -- | -- | -- | -- | -- | -- | Ann. Volatility | -- | -- | -- | -- | -- | -- | -- | -- |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.00 | 0% |
| MSCI EAFE | 0.00 | 0% |
| MSCI Emg Mkts | 0.00 | 0% |
Liquidity Measures
| Avg. volume (000) | 8 |
| ADV traded (mns) | $0 |
| Turnover | 6.7% |
| Avg. Bid/Ask (% of price) | 0.42% |
Technical Indicators
| 30d moving avg. (EMA) | $0.00 |
| Relative strength (RSI) | 0 |
| MACD/Signal | 0.00/0.00 |
| Bollinger Bands (Upper/Lower) | $0.00/$0.00 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PEPT |
Expenses vs. PEPT |
ALTAR Score™ vs. PEPT |
|---|---|---|---|---|
| OZEM | Roundhill GLP-1 & Weight Loss ETF | 34.6% | -6 bp | +2.1% |
| THNR | Amplify Weight Loss Drug & Treatment ETF | 27.7% | -6 bp | +3.1% |
| PPH | VanEck Pharmaceutical ETF | 18.9% | -29 bp | +5.7% |
| MEDI | Harbor Health Care ETF | 16.0% | +15 bp | -2.3% |
| PBPH | Portfolio Building Block World Pharma and Biotech Index ETF | 15.4% | -52 bp | +4.6% |
| IHE | iShares U.S. Pharmaceuticals ETF | 14.5% | -28 bp | +4.0% |
| YUNG | Corgi Longevity Consumer ETF | 14.2% | -30 bp | +2.5% |
| FHLC | Fidelity MSCI Health Care Index ETF | 13.9% | -57 bp | +3.6% |
| VHT | Vanguard Health Care ETF | 13.9% | -56 bp | +3.5% |
| HRTS | Tema Heart & Health ETF | 13.8% | +34 bp | +0.6% |
Risk and Returns: PEPT vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/17/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
1.2%
ALTAR SCORE™
9th
PERCENTILE
AVOID
ETFRC RATING
There are 765 funds in the Global Equity category with an average
ALTAR Score™ of 4.8% and a standard deviation
of 2.6%. PEPT's ALTAR Score™ is approximately -1.4 standard
deviations above the category average. This places PEPT in the 9th percentile
among funds in the category.
Sell-Side Consensus
$34.48
PRICE TARGET
+26.0%
UPSIDE